CoronaryAtlas logo
CoronaryAtlas
Urotensin II
Pathway / Endothelial activation & erosion

Urotensin II

peptide

Urotensin II promotes vasoconstriction and endothelial activation, contributing to coronary atherosclerotic disease.

Pathway placement
Cascade stepEndothelial activation & erosion
Confidencemedium
RationaleVasoconstriction and endothelial dysfunction; coronary artery disease association.
Also acts inVascular inflammation, Platelet activation
Druggability
Not assessed (no mapped human gene target).

Type I vs Type II discrimination

ScoresLow-confidence (proxy)
R — rupture / Type-I
35
C — confounder / Type-II
53
A — assay feasibility
66
E — evidence strength
21
T1DI (composite)
6
Specificity differential (R−C)-18.3
Confounder panel (Type-II drivers)
No confounder evidence retrieved.
Tier: light (literature co-occurrence proxy — lower confidence). See the discrimination table for all markers.

Assay & specimen

Class-level default (no specific cleared assay)— generic method inferred from analyte class; confirm against a specific product insert before use.
Specimen
Plasma (EDTA; peptidase-labile — chilled + protease inhibitor)
Collection tube
K2-EDTA, chilled plastic (lavender-top) · Serum separator (gold/red-top, SST)
Method / principle
Competitive/sandwich immunoassay or LC-MS/MS
Reagent / substrate
Anti-peptide antibody; or isotope-labeled internal standard (MS)
Platform
Immunoassay / LC-MS/MS
Turnaround · availability
Send-out / research · Research-grade

Literature evidence(2)